94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Mol. Biosci.
Sec. Molecular Diagnostics and Therapeutics
Volume 12 - 2025 | doi: 10.3389/fmolb.2025.1577764
Corrigendum: Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis
Provisionally accepted- Anhui Medical University, Hefei, China
Incorrect Funding In the published article, there was an error in the Funding statement. This study was supported by the National Natural Science Foundation of China (No. 8177140241). The correct Funding statement appears below.FUNDINGThis study was supported by the National Natural Science Foundation of China (No. 81774051).The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: arrb1, Pan-cancer, prognosis, tumor immunity, biomarker
Received: 16 Feb 2025; Accepted: 17 Feb 2025.
Copyright: © 2025 Ye, Jiang, Wu, Wang, Huang, Sun and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Mei Zhang, Anhui Medical University, Hefei, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.